To explore the relationship between blood eosinophil counts, asthma exacerbations and patient asthma control using a large primary care based research database
Sputum eosinophil levels have been shown to predict asthma exacerbation and inhaled corticosteroid (ICS) responsivenesss. Managing asthma based on sputum eosinophils leads to fewer exacerbations than management adhering to Global Initiative for Asthma (GINA) guidelines. However the use of sputum to measure eosinophil levels is expensive and impractical within a clinical setting. This study explores the use of blood-eosinophil levels as a clinical predictor for exacerbations and asthma control within a UK primary care dataset.
Study Type
OBSERVATIONAL
Enrollment
130,248
Research in Real Life Ltd
Cambridge, United Kingdom
Exacerbations
Defined as: * American Thoracic Society / European Respiratory Society (ATS/ERS) task force definition: Asthma related hospital admissions OR accident and emergency (A\&E) room attendance OR Use of acute oral steroids * Clinical definition: ATS/ERS definition including any GP consultations for lower respiratory related tract infections (LRTIs) treated with antibiotics
Time frame: 1 year
Asthma control
Defined as: * Risk domain asthma control: No Asthma-related hospital attendance, A\&E attendance, out-patient department attendance, no prescriptions for acute oral steroids and no GP consultations for LRTIs treated with antibiotics * Overall asthma control: Risk domain asthma control definition, including average daily dose of ≤200mcg salbutamol
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.